Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans

@inproceedings{OBrien2009AdenovirusSpecificIF,
  title={Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans},
  author={Kara L. O’Brien and Jinyan Liu and Sharon L. King and Yiming Sun and Joern E Schmitz and Michelle A. Lifton and Natalie A. Hutnick and Michael R Betts and Sheri A. Dubey and Jaap Goudsmit and John Shiver and Michael N. Robertson and Danilo R. Casimiro and Dan H Barouch},
  booktitle={Nature Medicine},
  year={2009}
}
The immunologic basis for the potential enhanced HIV-1 acquisition in adenovirus serotype 5 (Ad5)-seropositive individuals who received the Merck recombinant Ad5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5-seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5-seronegative subjects after vaccination… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-7 of 7 references

Br I E F Communicat Ions Nature Medicine Volume

  • M. Perreau, G. Pantaleo, E. J. Kremer
  • J. Exp. Med. 205,
  • 2008

Safety and immunogenicity of a replicationincompetent adenovirus type 5 HIV - 1 clade B gag / pol / nef vaccine in healthy adults

  • F. H. Priddy
  • Clinical infectious diseases
  • 2008

Quantifying adenovirusneutralizing antibodies by luciferase transgene detection : addressing preexisting immunity to vaccine and gene therapy vectors

  • M. C. Sprangers
  • J Clin Microbiol
  • 2003

Similar Papers

Loading similar papers…